On 23 June the UK electorate will make the vital decision about whether the country should stay within the European Union (EU) or leave it, and if one thing is clear it is that the pharmaceutical industry – largely – wants the UK to stay put.
While the Association of the British Pharmaceutical Industry (ABPI), by 1 April, had not taken a definitive stance – officials said it was still consulting with company members – the European Federation of Pharmaceutical Industries and Associations (EFPIA) has released a statement stressing that ‘the UK’s continued membership of the EU is in the best interests of the pharmaceutical industry in the UK and across Europe.’
It said that as part of the EU, British pharma companies would continue to benefit from pan-European collaborations in R&D, EU markets, the EU’s advocacy on global trade issues and harmonised European regulations. And it highlighted what is probably the biggest concern within the pharma sector faced with the uncertainty of a ‘Brexit’ vote: what happens next, and what would be the shape of the UK’s final relations with the 27 countries remaining in the EU?
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.